Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 20/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4295620 | 0.81 | HRH3 (1.00) | HRH3HRH1KCNH2 | |
| SCHEMBL5261750 | 0.81 | HRH3 (1.00) | HRH3 | |
| SCHEMBL6636102 | 0.78 | HRH3 (1.00) | HRH3HRH1KCNH2 | |
| SCHEMBL12050645 | 0.78 | HRH3 (1.00) | HRH3HRH1KCNH2 | |
| SCHEMBL4094339 | 0.78 | HRH3 (1.00) | HRH3HRH1KCNH2 | |
| SCHEMBL4089489 | 0.76 | HRH3 (0.84) | HRH3HRH1KCNH2 | |
| SCHEMBL12050718 | 0.76 | HRH3 (0.96) | HRH3HRH1KCNH2 | |
| SCHEMBL4090418 | 0.76 | HRH3 (0.73) | HRH3HRH1KCNH2 | |
| SCHEMBL5262552 | 0.75 | HRH3 (0.63) | HRH3HRH1KCNH2 | |
| SCHEMBL491626 | 0.75 | HRH3 (1.00) | HRH3HRH1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1268479-B1 | PHENYL-SUBSTITUTED INDOLIZINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 LIGANDS | ORTHO MCNEIL PHARM INC (US) | 2004-01-28 | — | — | EP | claimed |
| EP-1268479-A1 | PHENYL-SUBSTITUTED INDOLIZINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 LIGANDS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-01-02 | — | — | EP | claimed |
| US-20010051632-A1 | Phenyl-substituted indolizines and tetrahydroindolizines | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2001-12-13 | — | — | US | claimed |
| WO-2001074814-A1 | PHENYL-SUBSTITUTED INDOLIZINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 LIGANDS | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2001-10-11 | — | — | WO | claimed |
| EP-1268479-B1 | PHENYL-SUBSTITUTED INDOLIZINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 LIGANDS | ORTHO MCNEIL PHARM INC (US) | 2004-01-28 | — | — | EP | disclosed |
| EP-1268479-A1 | PHENYL-SUBSTITUTED INDOLIZINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 LIGANDS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-01-02 | — | — | EP | disclosed |
| US-20010051632-A1 | Phenyl-substituted indolizines and tetrahydroindolizines | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2001-12-13 | — | — | US | disclosed |
| WO-2001074814-A1 | PHENYL-SUBSTITUTED INDOLIZINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 LIGANDS | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051632-A1 | Phenyl-substituted indolizines and tetrahydroindolizines | TPH2, TPH1, IDO2 | HRH3 406/4885HRH1 418/4885KCNH2 1525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.